ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Scipher Medicine Increases Patient Access for PrismRA® by Expanding Intended Use in Autoimmune Patients
July 30, 2021Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA. -
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test
June 16, 2021Scipher today announced that in an independent validation study, PrismRA accurately predicted which patients with rheumatoid arthritis would not achieve EULAR good response criteria at six months of treatment using either adalimumab or etanercept.
Pharma Sources Insight January 2025
